Skip to main content
COCP
NASDAQ Life Sciences

Cocrystal Q3 Loss Widens to $3.4M; Going Concern Reiterated With $4.9M Cash

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Negative
Importance info
8
Price
$0.97
Mkt Cap
$18.88M
52W Low
$0.76
52W High
$2.03
52W Position info
28% above low
Off High info
52% below high
Rel. Volume info
0.3× avg
Market data snapshot near publication time

COCP sits 28% above its 52-week low of $0.76 on light trading volume (0.3× avg).

Summary

Cocrystal's Q3 2026 10-Q shows a $3.4M quarterly loss, $4.9M of cash and restricted cash, and a reiterated going-concern warning with less than 12 months of runway. The Phase 1b norovirus study has finished dosing and is moving to topline analysis.


Key Events · Earnings and Guidance · COCP

  • Q3 Loss Widens to $3.4M

    Net loss was $3.444M for the three months ended September 30, 2026, versus $2.049M a year earlier; nine-month loss reached $8.907M versus $6.405M.

  • Cash Falls to $4.9M, Runway Under 12 Months

    Cash and restricted cash were $4.948M at September 30, 2026, down from $7.100M at December 31, 2025, after $7.152M of operating cash burn. Management states current resources will not fund operations for at least the next 12 months.

  • Going Concern Warning Reiterated

    The 10-Q repeats substantial doubt about the ability to continue as a going concern, noting the auditor's explanatory paragraph on the December 31, 2025 financial statements.

  • OPKO Placement Added $5.0M in July

    On July 31, 2026 the company sold 5,474,053 shares to OPKO Health at $0.9134 per share for $5.0M gross, a related-party transaction with Dr. Phillip Frost.


Analysis · COCP · Life Sciences

Cocrystal burned $7.2M of operating cash in nine months and ended September with $4.9M in cash and restricted cash, which management says will not fund operations for the next 12 months. The going-concern warning is not new, but the runway is now short enough that another raise is near-certain, and any equity financing at today's price would be heavily dilutive. The one offset is clinical progress: the Phase 1b norovirus challenge study finished dosing in September and is heading into topline analysis, a potential value inflection if the data hold up.

How filings like this one have moved

In the 30 days to Nov 15, 2026, 48.2% of the 1980 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.20%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, COCP was trading at $0.97 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $18.9M. The 52-week trading range was $0.76 to $2.03. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

COCP - Latest Insights

COCP
Sep 09, 2026, 8:00 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $1.13
Real-time Price: $0.970 info
Change: -$0.160 (-14%) info
Market Cap: $18.88M info
COCP
Aug 13, 2026, 7:29 AM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $1.08
Real-time Price: $0.970 info
Change: -$0.110 (-10%) info
Market Cap: $18.88M info
COCP
Aug 07, 2026, 5:11 PM EDT
Filing Type: SCHEDULE 13D/A
Importance Score:
7
Price at Filing: $1.06
Real-time Price: $0.970 info
Change: -$0.090 (-8%) info
Market Cap: $18.88M info
COCP
Aug 03, 2026, 7:15 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $0.8463
Real-time Price: $0.970 info
Change: +$0.1237 (+15%) info
Market Cap: $18.88M info
COCP
Jun 09, 2026, 7:00 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $0.990
Real-time Price: $0.970 info
Change: -$0.020 (-2%) info
Market Cap: $18.88M info